Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials

Vedolizumab immunogenicity has been assessed using an enzyme-linked immunosorbent assay (ELISA) with a ~ 0.5 μg/mL drug interference, which may underestimate on-drug immunogenicity. We aimed to compare immunogenicity results between ELISA and the new drug-tolerant electrochemiluminescence (ECL) assa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyant, Timothy, Yang, Lili, Rosario, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669784/
https://www.ncbi.nlm.nih.gov/pubmed/33200296
http://dx.doi.org/10.1208/s12248-020-00518-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669784/
https://www.ncbi.nlm.nih.gov/pubmed/33200296
http://dx.doi.org/10.1208/s12248-020-00518-0

Ejemplares similares